20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Vor Biopharma Inc (VOR) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 76 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, VOR reported $0M in revenue and ($696M) in net income.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | ($4M) | ($3M) | ($9M) | ($4M) | ($1M) | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($147M) | ($372M) | ($121M) | ($126M) | ($93M) | ($69M) | ($43M) | ($10M) | ($3M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — |
| Net Income | $628M | ($696M) | ($117M) | ($118M) | ($92M) | ($69M) | ($43M) | ($11M) | ($4M) |
| Net Margin % | — | — | — | — | — | — | — | — | — |
| EBITDA | $643M | ($693M) | ($113M) | ($114M) | ($83M) | ($67M) | ($43M) | ($10M) | ($3M) |
| Earnings Per Share (EPS) | $-458.79 | $-70.50 | $-34.03 | $-35.08 | $-46.57 | $-37.07 | $-23.34 | $-5.84 | $-14.67 |
| Shares Outstanding (M) | 54M | 10M | 3M | 3M | 2M | 2M | 2M | 2M | 0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $4M | $0M |
| Gross Profit | — | $0M | $0M | — | ($2M) | ($1M) | ($1M) | ($1M) |
| Gross Margin % | — | — | — | — | — | — | -23.5% | — |
| Operating Income (EBIT) | ($48M) | ($35M) | ($36M) | ($28M) | ($274M) | ($33M) | ($31M) | ($29M) |
| Operating Margin % | — | — | — | — | — | — | -849.5% | — |
| Net Income | ($63M) | ($220M) | $1.7B | ($813M) | ($1.6B) | ($32M) | ($31M) | ($28M) |
| Net Margin % | — | — | — | — | — | — | -833.2% | — |
| EBITDA | ($48M) | ($220M) | $1.7B | ($813M) | ($242M) | ($32M) | ($30M) | ($27M) |
| Earnings Per Share (EPS) | $-1.16 | $-510.53 | $174.52 | $-121.63 | $-251.24 | $-5.21 | $-8.94 | $-8.05 |
| Shares Outstanding (M) | 54M | 0M | 10M | 7M | 6M | 6M | 3M | 3M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($140M) | ($143M) | ($100M) | ($100M) | ($85M) | ($69M) | ($36M) | ($10M) | ($3M) |
| Capital Expenditures (CapEx) | $1M | $1M | $0M | $1M | $8M | $4M | $4M | $1M | $1M |
| Free Cash Flow (FCF) | ($141M) | ($144M) | ($100M) | ($101M) | ($94M) | ($73M) | ($40M) | ($11M) | ($3M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($26M) | ($38M) | ($23M) | ($54M) | ($35M) | ($31M) | ($24M) | ($23M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($26M) | ($38M) | ($23M) | ($54M) | ($35M) | ($31M) | ($24M) | ($23M) |
| FCF Margin % | — | — | — | — | — | — | -654.8% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $481M | $464M | $143M | $210M | $299M | $243M | $76M | $10M | $1M |
| Cash & Cash Equivalents | $108M | $396M | $82M | $31M | $58M | $120M | $49M | $6M | $1M |
| Total Liabilities | $681M | $628M | $46M | $59M | $49M | $26M | $28M | $2M | $8M |
| Total Debt (Short + Long-Term) | $0M | $0M | $4M | $4M | $3M | $2M | $1M | $0M | $4M |
| Total Shareholders' Equity | ($200M) | ($164M) | $97M | $151M | $251M | $216M | $48M | $8M | ($7M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VOR viewer.
About TickerBase · Data methodology & sources · Privacy · Terms